Shareholders who purchased shares of HUM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. ALLEGATIONS: According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Specifically, defendants downplayed pressures on the Company's adjusted earnings per share resulting from increased medical costs associated with pent-up ...